Comprehensive Analysis of Fecal Calprotectin Test Market Including Regional and Country Analysis in Brief.
Industry: Healthcare
Published Date: April-2025
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 180
Report ID: PMRREP35197
The global fecal calprotectin test market is projected to witness a CAGR of 8.9% from 2025 to 2032. It is anticipated to increase from US$4,728.3 Mn recorded in 2025 to a staggering US$9,623.7 Mn by 2032.
The fecal calprotectin test market as a service is growing due to the increasing demand for non-invasive diagnostic solutions for inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, according to Persistence Market Research report. Service-based businesses cater to hospitals, diagnostic laboratories, and specialized gastrointestinal clinics offering outsourced testing solutions eliminate the need for in-house lab infrastructure. This approach enhances patient accessibility ensuring accurate and timely results for healthcare providers.
Key Industry Highlights:
|
Global Market Attribute |
Key Insights |
|
Market Size (2025E) |
US$ 4,728.3 Mn |
|
Market Value Forecast (2032F) |
US$ 9,623.7 Mn |
|
Projected Growth (CAGR 2025 to 2032) |
8.9% |
|
Historical Market Growth (CAGR 2019 to 2024) |
7.5% |
Adopting subscription-based diagnostic services for fecal calprotectin testing is transforming chronic disease management, particularly for inflammatory bowel disease (IBD) patients. These services provide monthly or quarterly at-home test kits, enabling patients to track their inflammatory markers without frequent hospital visits. By integrating with telehealth platforms, subscription-based models allow seamless remote consultations, where gastroenterologists can analyze test results, detect early signs of flare-ups, and adjust treatment strategies in real time.
This proactive approach enhances patient convenience and reduces the burden on healthcare facilities, lowering emergency hospital admissions due to undiagnosed disease progression. Additionally, AI-powered dashboards are now integrated into these services and offer qualitative data for trend analysis of inflammation levels and predictive insights for personalized disease management.
Variability in stool sample collection and handling presents a significant challenge in the adoption of fecal calprotectin testing, as improper collection techniques can lead to inaccurate results, reducing the test reliability. Unlike blood or urine samples, stool consistency and composition can vary significantly among patients, affecting calprotectin concentration measurements. Factors such as diet, hydration levels, and transit time in the gut can alter the sample composition, making standardization difficult. Additionally, patients struggle with proper sample collection, leading to contamination, insufficient sample volume, or degradation of biomarkers before laboratory analysis.
Improper storage and transportation further exacerbate this issue. Since fecal calprotectin is a protein susceptible to degradation, delays in sample processing or exposure to temperature fluctuations can result in false-negative or misleading results. This inconsistency undermines physician confidence in the test, prompting some healthcare providers to favor more invasive diagnostic method such as endoscopy. Moreover, laboratory discrepancies in extraction protocols and analysis methods create further variability, limiting the widespread acceptance of fecal calprotectin testing as a diagnostic standard.
Enzyme-linked immunosorbent assay (ELISA) leads the technique segment in the fecal calprotectin test market as a service-based market due to its high sensitivity, cost-effectiveness, and ability to handle large sample volumes efficiently. ELISA offers a standardized and automated approach, making it the preferred choice for diagnostic laboratories and service providers. Unlike lateral flow assays, which provides qualitative or semi-quantitative results, ELISA delivers precise and reproducible quantitative measurements of fecal calprotectin levels, improving diagnostic accuracy for inflammatory bowel diseases (IBD). Furthermore, ELISA-based fecal calprotectin tests are compatible with high-throughput screening, enabling service providers to process multiple samples simultaneously, reducing turnaround time and operational costs.
Inflammatory bowel disease (IBD) leads the indication segment in the fecal calprotectin test market as a service-based market due to its growing global prevalence and the need for non-invasive diagnostic and monitoring solutions. Unlike irritable bowel syndrome (IBS) or other gastrointestinal disorders, IBD, comprising Crohn’s disease and ulcerative colitis requires frequent disease activity assessment to guide treatment decisions. Fecal calprotectin testing is a preferred option as it differentiates between inflammatory and non-inflammatory conditions, reducing unnecessary endoscopic procedures.
Additionally, IBD management relies on continuous monitoring to evaluate treatment efficacy and predict disease flares, making fecal calprotectin testing a cost-effective and patient-friendly alternative to repeated invasive tests.
North America dominates the fecal calprotectin test market as a service-based industry due to its advanced healthcare infrastructure, high disease prevalence, and increasing reliance on diagnostic outsourcing. The region has a well-established network of reference laboratories and diagnostic service providers, allowing for widespread accessibility to fecal calprotectin testing without the need for in-house hospital diagnostics. The rising incidence of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis has driven demand for non-invasive biomarkers, with fecal calprotectin emerging as a preferred diagnostic tool.
According to the CDC in 2024, IBD affected approximately three million adults in the U.S., creating a strong need for outsourcing diagnostic services. Additionally, favorable reimbursement policies from private and public insurers encourage clinicians to recommend fecal calprotectin tests, boosting service-based testing volumes.
Europe is the second-leading region in the fecal calprotectin test market due to a combination of strong healthcare infrastructure, high prevalence of inflammatory bowel diseases (IBD), and government-backed reimbursement policies. Countries such as Germany, the UK, and France have well-established diagnostic services enabling the widespread adoption of fecal calprotectin testing, particularly in primary and secondary healthcare settings.
The growing burden of Crohn’s disease and ulcerative colitis in Europe, with an estimated prevalence of over 3.4 million cases drives demand for non-invasive biomarkers such as fecal calprotectin, reducing the need for more invasive diagnostic procedures such as endoscopy. Additionally, Europe's stringent clinical guidelines, such as those issued by the European Crohn’s and Colitis Organization (ECCO), encourage the routine use of fecal calprotectin tests for monitoring disease progression, further accelerating market adoption.
Asia Pacific is rapidly emerging as a key market for fecal calprotectin testing services, driven by the increasing prevalence of gastrointestinal disorders and the rising burden of inflammatory bowel disease (IBD). The shift towards early disease detection and non-invasive diagnostics has fueled demand for fecal calprotectin tests, particularly in urban centers where healthcare accessibility is improving.
Japan and South Korea lead in advanced diagnostic services with well-established laboratory infrastructure and government-supported insurance schemes covering biomarker-based tests. Meanwhile, India and Southeast Asian countries are experiencing strong growth due to the expansion of private diagnostic labs offering cost-effective fecal calprotectin testing as a service. The increasing adoption of outsourced laboratory testing models in hospitals and clinics has further propelled market expansion, enabling faster and more efficient diagnostics.
The global fecal calprotectin test market is highly competitive, with key players focusing on expanding laboratory networks, automation, and AI-driven diagnostics. Strategic collaborations between hospitals and third-party labs continue to shape market dynamics, making innovation and cost-efficiency a key differentiator in this evolving landscape.
|
Report Attribute |
Details |
|
Historical Data/Actuals |
2019 - 2024 |
|
Forecast Period |
2025 - 2032 |
|
Market Analysis Units |
Value: US$ Mn |
|
Geographical Coverage |
|
|
Segmental Coverage |
|
|
Competitive Analysis |
|
|
Report Highlights |
|
|
Customization and Pricing |
Available upon request |
By Technique
By Indication
By End-user
By Region
To know more about delivery timeline for this report Contact Sales
The global fecal calprotectin test market is estimated to increase from US$4,728.3 Mn in 2025 to US$9,623.7 Mn in 2032.
The increasing incidence of inflammatory bowel disease (IBD), Crohn’s disease, and ulcerative colitis is a major driver. Over 10 million people worldwide are affected by IBD, which fuels the need for non-invasive diagnostics such as fecal calprotectin testing.
The market is projected to record a CAGR of 8.9% during the forecast period from 2025 to 2032.
The growing demand for convenient and patient-friendly diagnostics is creating opportunities for home-based fecal sample collection kits. Medical companies are investing in telehealth integration and AI-driven analysis to enhance accessibility.
The key players in the fecal calprotectin market include Epitope Diagnostics Inc., Hycult Biotech, Actim, OPERON, Svar Life Science, and others.
